These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

939 related articles for article (PubMed ID: 36400097)

  • 1. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
    Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
    Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A cross-sectional study on the prevalence rate and influencing factors of non-alcoholic fatty liver disease in overweight/obese children].
    Dai W; Yao ZZ; Ou-Yang SS; Xu NA; Zhou HX; Li XW; Zhong Y; Luo JY
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 May; 25(5):448-456. PubMed ID: 37272169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis.
    Abeysekera KWM; Orr JG; Gordon FH; Howe LD; Hamilton-Shield J; Heron J; Hickman M
    BMC Gastroenterol; 2022 Jun; 22(1):323. PubMed ID: 35773644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of whole blood copper, zinc, calcium, magnesium, and iron with non-alcoholic fatty liver disease in overweight and obese children.
    Huang Z; Luo M; Dai W; Yao Z; Ouyang S; Xu N; Zhou H; Li X; Zhong Y; Luo J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Mar; 49(3):426-434. PubMed ID: 38970517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
    En Li Cho E; Ang CZ; Quek J; Fu CE; Lim LKE; Heng ZEQ; Tan DJH; Lim WH; Yong JN; Zeng R; Chee D; Nah B; Lesmana CRA; Bwa AH; Win KM; Faulkner C; Aboona MB; Lim MC; Syn N; Kulkarni AV; Suzuki H; Takahashi H; Tamaki N; Wijarnpreecha K; Huang DQ; Muthiah M; Ng CH; Loomba R
    Gut; 2023 Nov; 72(11):2138-2148. PubMed ID: 37491159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
    Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
    J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
    Chakrabarty M; Jha AN; Sharma DJ
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design.
    Xu ZJ; Shi JP; Yu DR; Zhu LJ; Jia JD; Fan JG
    Adv Ther; 2016 Nov; 33(11):2069-2081. PubMed ID: 27743352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of serum ferritin with non-alcoholic fatty liver disease: a meta-analysis.
    Du SX; Lu LL; Geng N; Victor DW; Chen LZ; Wang C; Yue HY; Xin YN; Xuan SY; Jin WW
    Lipids Health Dis; 2017 Dec; 16(1):228. PubMed ID: 29197393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
    Younossi Z; Aggarwal P; Shrestha I; Fernandes J; Johansen P; Augusto M; Nair S
    JHEP Rep; 2022 Sep; 4(9):100525. PubMed ID: 36039144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.
    Tan DJH; Ng CH; Lin SY; Pan XH; Tay P; Lim WH; Teng M; Syn N; Lim G; Yong JN; Quek J; Xiao J; Dan YY; Siddiqui MS; Sanyal AJ; Muthiah MD; Loomba R; Huang DQ
    Lancet Oncol; 2022 Apr; 23(4):521-530. PubMed ID: 35255263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between MBOAT7 rs641738 polymorphism and non-alcoholic fatty liver in overweight or obese children.
    Zusi C; Morandi A; Maguolo A; Corradi M; Costantini S; Mosca A; Crudele A; Mantovani A; Alisi A; Miraglia Del Giudice E; Targher G; Maffeis C
    Nutr Metab Cardiovasc Dis; 2021 May; 31(5):1548-1555. PubMed ID: 33810963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis-A Systematic Review, Meta-Analysis and Meta-Regression.
    Gudan A; Jamioł-Milc D; Hawryłkowicz V; Skonieczna-Żydecka K; Stachowska E
    Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid.
    Eshraghian A; Nikeghbalian S; Geramizadeh B; Kazemi K; Shamsaeefar A; Malek-Hosseini SA
    Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):572-578. PubMed ID: 31611031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
    Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
    J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults.
    Liu J; Ayada I; Zhang X; Wang L; Li Y; Wen T; Ma Z; Bruno MJ; de Knegt RJ; Cao W; Peppelenbosch MP; Ghanbari M; Li Z; Pan Q
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e573-e582. PubMed ID: 33618024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The value of different insulin resistance indices in assessment of non-alcoholic fatty liver disease in overweight/obese children.
    El-Karaksy HM; El-Raziky MS; Fouad HM; Anwar GM; El-Mougy FM; El-Koofy NM; El-Hennawy AM
    Diabetes Metab Syndr; 2015; 9(2):114-9. PubMed ID: 25470627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.